NCT00441246

Phase 4 Study - Mucinex D as Adjunct Therapy

A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Mucinex D as Adjunct Therapy to Antibiotic Treatment of Acute Respiratory Infection

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: Adams Respiratory Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection.

Conditions

• Acute Respiratory Infection
• Bronchitis
• Rhinosinusitis

Interventions

Type	Name	Description
DRUG	Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)

Timeline

• Start date: 2007-02-01
• Primary completion: 2007-05-01
• Completion: 2007-07-01
• First posted: 2007-02-28
• Last updated: 2008-02-06

Locations

28 sites across 1 country: United States